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Reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) can be achieved by viral-mediated
transduction of defined transcription factors. Moving toward the eventual goal of clinical application, it is
necessary to overcome limitations such as low reprogramming efficiency and genomic alterations due to viral
integration. Here, we review recent progress made in the usage of genetic factors, chemical inhibitors,
and signaling molecules that can either replace core reprogramming factors or enhance reprogramming
efficiency. Current iPSC studies will provide a paradigm for the combinatorial use of genetic factors and
chemicals for the broader applications to alter cellular states of potency.pluripotency: specifically, in vitro differentiation into cell types
of the three germ layers, teratoma formation, contribution to
chimeras, germline transmission (Maherali and Hochedlinger,
2008), and tetraploid complementation (Woltjen et al., 2009).
Subsequent studies have shown that human iPSCs could be
obtained using similar transduction methods (Lowry et al.,
2008; Park et al., 2008; Takahashi et al., 2007; Yu et al.,
2007b). The progress from mouse to human iPSCs has opened
the possibility of autologous regenerative medicine whereby
patient-specific pluripotent cells could be derived from adult
somatic cells. Several limitations of most existing iPSCs prohibit
their usage in the clinical setting (Maherali and Hochedlinger,
2008). First, virus-mediated delivery of reprogramming factors
introduces unacceptable risks of permanent transgene integra-
tion into the genome. The resulting genomic alteration and
possible reactivation of viral transgenes pose serious clinical
concerns. Second, reprogramming factors Klf4 and c-Myc are
oncogenic. Third, iPSC reprogramming is an inefficient and
slow process. During the course of reprogramming, a substantial
reduction in efficiency may also result from incomplete reprog-
ramming (Mikkelsen et al., 2008; Okita et al., 2007; Silva et al.,
2008). Before iPSCs can fulfill their potential in custom-tailored
cell therapy, strategies must be devised to resolve these issues.
Consistent with the fast-moving pace of the reprogramming
field, considerable progress has already been made toward
achieving these goals. Herein, we review the recent advances
made in reprogramming with a focus on the identification of
molecules (genetic factors, small molecules, or signaling
molecules) that can promote or enhance reprogramming. The
potential mechanisms by which reprogramming factors and
small molecules may participate in reprogramming will also be
discussed.
Factors that Permit Reprogramming
While iPSC reprogramming was originally performed using a set
of transcription factors that consisted of Oct4, Sox2, Klf4, and
c-Myc (Takahashi and Yamanaka, 2006), these transcriptionMammalian development involves a progressive restriction of
developmental potential as the totipotent zygote transits through
the pluripotent inner cell mass (ICM) and eventually gives rise to
a multitude of differentiated cell types that generally lack the
ability to revert back to a less specialized state. Embryonic
stem cells (ESCs) derived from the ICM of blastocyst stage
embryos can be propagated in vitro, and these cells retain pluri-
potency, which is the capability to give rise to all cell types of the
embryo proper (Rossant, 2008). These features of ESCs have
made them an attractive tool for early developmental studies
as well as a resource for potential applications in regenerative
medicine. Over the last decade, much effort has been made to
better understand themolecular circuitry of ESCs. The transcrip-
tion factor trio, Oct4, Sox2, and Nanog, have been established
as the core transcription factors that govern pluripotency (Jae-
nisch and Young, 2008). Besides extending autoregulatory and
feed-forward loops, Oct4, Sox2, and Nanog also extensively
cotarget downstream genes (Boyer et al., 2005; Chen et al.,
2008; Kim et al., 2008a; Loh et al., 2006).
Although differentiation is generally irreversible under physio-
logical contexts, several methods have been developed to
reprogram somatic cells. Herein, reprogramming refers to the
reversion of somatic cells into a less differentiated state or
stem-cell-like state. Reprogramming methodologies, such as
somatic cell nuclear transfer, have proved successful for several
species, but there are technical and ethical issues in applying
this approach to human cells (Yamanaka, 2007). In a ground-
breaking study, Yamanaka and Takahashi converted mouse
somatic cells to ESC-like cells with expanded developmental
potential using only four transcription factors (Takahashi and
Yamanaka, 2006). This induced pluripotencymethod is achieved
by the direct transduction of Oct4, Sox2, Klf4, and c-Myc
(OSKM) and has ignited immense excitement as a robust reprog-
ramming technique (Maherali and Hochedlinger, 2008). These
iPSCs closely resemble ESCs as they restore the pluripotency-
associated transcriptional circuitry and epigenetic landscape.
In addition, mouse iPSCs satisfy all the standard assays forCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 301
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Factors Function
Yamanaka
Factors Used
Species and Cell
Type Comments References
LIN28, NANOG ESC-specific RNA-binding
protein and ESC-specific
transcription factor,
respectively
OS human
fibroblast
both are together able to
replace K and M
(Yu et al., 2007b)
Esrrb orphan nuclear receptor OSM, OS mouse
fibroblast
Esrrb is able to replace K (Feng et al., 2009)
Pax5 shRNA,
C/EBPa
B cell transcription factor
and myeloid transcription
factor, respectively
OSKM mouse B cell full B cell reprogramming
requires Pax5 RNAi or C/EBPa
expression
(Hanna et al., 2008)
p53 siRNA,
UTF1
tumor suppressor and
ESC-specific transcription
factor, respectively
OSKM human
fibroblast
100-fold increase in efficiency
for OSKM + p53 siRNA+UTF1
compared to OSKM
(Zhao et al., 2008)
OSK more than 100-fold increase in
efficiency for OSK+p53
siRNA+UTF1 compared to OSK
DNMT shRNA knockdown of DNA
methyltransferase
OSKM mouse
fibroblast
promotes full reprogramming. (Mikkelsen et al., 2008)
Wnt3a cell signaling molecule OSKM mouse
fibroblast
marginal increase in efficiency
with OSKM
(Marson et al., 2008)
OSK 20-fold increase in efficiency
with OSK
SV40 LT (T) SV40 large T antigen
that is used in cell
transformation
OSKM* human
fibroblast
23 (OSKM*+T)- to 70 (OS +
LIN28 + NANOG + T)-fold
increase in efficiency as
compared to OSKM* and OS +
LIN28 + NANOG respectively
(Mali et al., 2008)
OSM* 55-fold increase in efficiency
compared to OSKM* and able
to replace K
OS 9-fold increase in efficiency
compared to OSKM* and able
to replace K; M*; and LIN28,
NANOG
hTERT telomerase reverse
transcriptase
OSKM human
fibroblast
up to 3-fold increase in
efficiency of OSKM + hTERT + T
compared to OSKM
(Park et al., 2008)
O, Oct4; S, Sox2; K, Klf4; M, c-Myc; M*, N-Myc.302 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.Sox2, and Klf4. Besides these four factors, Thomson and
colleagues were able to reprogram human fibroblasts with
a distinct set of transcription factors comprising OCT4, SOX2,
NANOG, and LIN28 (OSNL), indicating that KLF4 and c-MYC
could be substituted with NANOG and LIN28 (Yu et al., 2007b).
In the context of mouse iPSC reprogramming, the ability to
replace Klf4 with other factors was recently demonstrated. Ng
and colleagues found that the orphan nuclear receptor, Esrrb,
can replace Klf4 in the reprogramming of mouse embryonic
fibroblasts (MEFs) when cotransduced with either OSM or OS
(Feng et al., 2009). Although Klf4 can be replaced by related
Kru¨ppel-like transcription factors (Klf2 and Klf5) (Nakagawa
et al., 2008), the finding that an unrelated transcription factor is
able to substitute for Klf4 is unexpected. Through knockdown
experiments, Esrrb was shown to be required for the mainte-
nance of self-renewal and pluripotency of ESCs (Ivanova et al.,
2006; Loh et al., 2006). More importantly, Esrrb positivelyfactors are not stringently necessary as some of them can be
replaced by other factors (Table 1). Although c-Myc was found
to be dispensable, it can improve the efficiency of reprogram-
ming (Nakagawa et al., 2008; Wernig et al., 2008). A recent study
from Plath and colleagues provided further insight into the roles
of the four reprogramming factors. They found that ectopic
expression of c-Myc promoted the most prominent ESC-like
expression pattern among the four factors when expressed
individually in fibroblasts, and c-Myc functions predominantly
prior to the induction of pluripotency regulators during reprog-
ramming (Sridharan et al., 2009). At the final phase of reprogram-
ming, Oct4, Sox2, and Klf4 re-establish an ESC-like association
with cobound target genes and activate the expression of other
pluripotency genes. In contrast, partially reprogrammed cells
lack similar cobinding activities and may reflect incomplete
epigenetic changes and/or the requirement for additional
induced factors to cooperatively bind target genes with Oct4,
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explain its ability to replace Klf4 in reprogramming (Feng et al.,
2009). In addition, Esrrb was also reported to function as a tran-
scriptional activator of other reprogramming genes such asOct4,
Sox2, and Nanog (van den Berg et al., 2008; Zhang et al., 2008).
Although Esrrb positively regulates Oct4 and Sox2 in mouse
ESCs, exogenous Oct4 and Sox2 are still required for reprog-
ramming in combination with Esrrb (Feng et al., 2009). It is prob-
able that the quantitative level of transcriptional activation of
both Oct4 and Sox2 by Esrrb is insufficient for reprogramming.
It is also noteworthy that three of the reprogramming factors
(Sox2, Nanog, and Esrrb) are physically associated with Oct4
(Liang et al., 2008; Wang et al., 2006). As Oct4 alone is not suffi-
cient to mediate reprogramming in MEFs, this observation
suggests that efficient activation of the pluripotency-associated
transcriptional circuitry may require the concurrent presence of
Oct4 and its associated factors to interact with greater specificity
at their cobound targets. Hence, it is conceivable that other novel
reprogramming factors can be uncovered through screening
transcription factors that are found within the Oct4 complex.
The identification of novel reprogramming factors will enhance
our understanding of the principles underlying reprogramming.
Numerous studies have demonstrated that different types of
somatic cells, including neural progenitor cells (NPCs), keratino-
cytes from the ectoderm (Aasen et al., 2008; Shi et al., 2008b),
progenitor B cells from the mesoderm (Hanna et al., 2008), as
well as stomach cells and hepatocytes from the endoderm (Aoi
et al., 2008), can all be reprogrammed using the same four tran-
scription factors, OSKM. Similarly, success has also been
reported in the rhesus monkey (Liu et al., 2008) and rat (Li et al.,
2009; Liao et al., 2009). Cell types that express high endogenous
levels of a particular transcription factor may not require certain
exogenous factors. For example, neural stem cells (NSCs) and
NPCs which express high levels of endogenous Sox2 and
c-Myc can be reprogrammed without the viral introduction of
exogenous Sox2 (Duinsbergen et al., 2008; Eminli et al., 2008;
Kim et al., 2008b). Two laboratories subsequently showed that
iPSCs could be generated from NSCs with just two factors:
either Oct4 and Klf4 (Kim et al., 2008b; Silva et al., 2008) or
Oct4 and c-Myc (Kim et al., 2008b).
More recently, Scho¨ler and colleagues further reduced the
number of required reprogramming factors (Kim et al., 2009).
Oct4 alone is sufficient to reprogram NSCs to iPSCs that are
capable of germline transmission. In addition to bypassing the
requirement for oncogenic factors Klf4 and c-Myc, one-factor
reprogramming reduces the number of transgene integrations.
Notably, the findings of this study also affirm the critical role of
Oct4 in the reprogramming of somatic cells, which generally
do not express or express very low levels of Oct4 (Lengner
et al., 2008). To date, no transcription factor has been found to
be able to replace Oct4 in reprogramming. Hence, it will be inter-
esting to determine if Oct4 could be substituted by other factors
or perhaps chemicals.
Factors and Strategies that Can Enhance
Reprogramming
The slow and inefficient process of reprogramming imposes limi-
tations to mechanistic studies and potential clinical translation.
This drawback has propelled the development of strategies toimprove the reprogramming efficiency, such as overexpression
or knockdown of additional factors (Table 1). The addition of
SV40 large T antigen (SV40 LT) and the catalytic subunit of the
human telomerase (hTERT) increased the reprogramming effi-
ciency of human fibroblasts in combination with either OSKM
or OSNL (Mali et al., 2008; Park et al., 2008), although genomic
integrations of the SV40 LT and hTERT transgenes were not
detected in the resulting iPSCs (Park et al., 2008). MEFs
harboring GFP gene under the control of an Oct4 promoter are
commonly used as reporter cells for reprogramming (Feng
et al., 2009; Huangfu et al., 2008a; Shi et al., 2008a). Induction
of the pluripotent state is accompanied by reactivation of the
Oct4-GFP reporter and generation of GFP-positive cells. By
inhibiting or knocking down DNA methyltransferase (DNMT),
a higher percentage of cells from partially reprogrammed cell
lines exhibit Oct4-GFP expression (Mikkelsen et al., 2008), sug-
gesting that reprogramming can be enhanced by the induction of
DNA demethylation. In another study, an approximately 100-fold
enhancement of reprogramming efficiency was observed when
the transduction of OSKM was combined with both p53 knock-
down and the introduction of UTF1 in human fibroblasts (Zhao
et al., 2008). Even when c-MYC was omitted in the reprogram-
ming cocktail, reprogramming efficiency was similarly increased
with the addition of UTF1 and p53 knockdown. Utf1 is known to
be a target gene of the Oct4-Sox2 heterodimer (Nishimoto et al.,
1999) and may, in turn, activate other downstream genes impor-
tant for promoting reprogramming. Inhibition of p53 could
interfere with the cellular apoptosis process, and the subsequent
promotion of cell survival may thus explain the improvement of
reprogramming efficiency. However, given the role of p53 in
regulating genomic integrity, there is a risk that these iPSCs
that have escaped apoptosis are abnormal.
Potential Roles of microRNAs in Reprogramming
Besides transcription factors and epigenetic modifiers, micro-
RNAs may play an equally important role in reprogramming,
commensurate with their emerging role in the maintenance of
ESCs (Ivey et al., 2008). Hitherto, only one particular microRNA,
mir-302, which is expressed abundantly in human ESCs, has
been implicated in reprogramming (Lin et al., 2008). mir-302
was able to convert human cancer cell lines to cells that resem-
bled ESCs. However, it remains unknown if mir-320 can repro-
gram primary cells to genuine iPSCs. On the other hand, the
downregulation of certain microRNAs may also be beneficial
for reprogramming. For example, the aforementioned reprog-
ramming gene Lin28 inhibits the biogenesis of the let7 family of
microRNAs (Newman et al., 2008; Viswanathan et al., 2008),
which has a role in the self-renewal of breast cancer cells (Yu
et al., 2007a). Therefore, Lin28may actually promote reprogram-
ming by the repression of differentiation induced by the let7
family of microRNAs. Systematic screening of microRNAs,
specifically ESC-specificmicroRNAs, for the enhancement of re-
programming efficiency or the replacement of reprogramming
factors could uncover newmicroRNAs that participate in reprog-
ramming.
Small Molecules in Reprogramming
In addition to strategies that utilize various transcription factors
and possibly microRNAs, it is imperative to devise alternativeCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 303
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Chemicals Function
Yamanaka Factors
Used
Species and Cell
Type Comments References
BIX-01294 G9a histone
methyltransferase
inhibitor
OK mouse fibroblast OK + BIX-01294 enhances
efficiency approximately five
times more than OK and is able
to replace S
(Shi et al., 2008a)
OK mouse NPC OK + BIX-01294 enhances
efficiency approximately 1.5
times more than OSKM and
approximately eight times more
than OK, and BIX-01294 is able
to replace S
(Shi et al., 2008b)
SKM able to replace O in NPC
reprogramming, but with
extremely low efficiency
BayK8644 L-type calcium
channel agonist
OK mouse fibroblast OK + BIX-01294 + BayK8644
enhances efficiency 15 times
more than OK
(Shi et al., 2008a)
RG108 DNA methyltransferase
inhibitor
OK mouse fibroblast OK + BIX-01294 + RG108
enhances reprogramming
efficiency 30 times more than
OK
(Shi et al., 2008a)
AZA DNA methyltransferase
inhibitor
OSKM mouse fibroblast 4-fold increase in efficiency
with OSKM and promotes full
reprogramming
(Mikkelsen et al., 2008)
10-fold increase in efficiency
with OSKM
(Huangfu et al., 2008a)
3-fold increase in efficiency
with OSK
dexamethasone steroid glucocorticoid OSKM mouse fibroblast increases the effect of 50
azacytidine by 2.6-fold
(Huangfu et al., 2008a)
VPA histone deacetylase
inhibitor
OSKM mouse fibroblast more than 100-fold increase
efficiency with OSKM
(Huangfu et al., 2008a)
OSK 50-fold increase in efficiency
with OSK
OSK human fibroblast 10- to 20-fold increase
compared to OSK
(Huangfu et al., 2008b)
OS VPA is able to replace K and M
TSA histone deacetylase
inhibitor
OSKM mouse fibroblast 15-fold increase in efficiency
with OSKM
(Huangfu et al., 2008a)
SAHA histone deacetylase
inhibitor
OSKM mouse fibroblast 2-fold increase in efficiency
with OSKM
(Huangfu et al., 2008a)
PD0325901 +
CHIR99021 (2i)
inhibitor of MEK and
GSK3 respectively
OK mouse NSC together with LIF, promote
ground state pluripotency in OK
pre-iPSCs.
(Silva et al., 2008)
mouse NPC PD0325901 promotes growth of
true iPSCs and inhibits growth of
non-iPSCs
(Shi et al., 2008b)
A-83-01 TGF-b inhibitor OSK rat liver progenitor together with LIF and 2i to
maintain mESC-like rat iPSCs
(Li et al., 2009)
human fibroblast Together with LIF and 2i to
maintain mESC-like human
iPSCs
O, Oct4; S, Sox2; K, Klf4; M, c-Myc.304 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.tute for specific reprogramming factors (Table 2). Among the
reported chemicals, some are known to affect chromatin modi-
fications while others influence signal transduction pathways.methods, such as using small molecules to promote reprogram-
ming (Xu et al., 2008). Several chemicals have recently been
reported to either enhance reprogramming efficiencies or substi-
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ReviewFigure 1. Promotion of Fully Competent Induced
Pluripotency and Acceleration of Reprogramming
Kinetics with Chemicals
In conventional reprogramming of somatic cells without
the addition of chemicals, many cells remain partially
reprogrammed (dashed lines). These partially reprog-
rammed cells that are also known as pre-/partial-iPSCs,
reflect intermediate stages of reprogramming. However,
with the addition of MEK inhibitor PD0325901 and GSK3
inhibitor CHIR99021 (collectively known as 2i) or AZA,
these pre-/partial-iPSCs could be further promoted to fully
competent iPSCs (black vertical arrows). Addition of
chemicals such as VPA or AZA could also accelerate the
kinetics of reprogramming by achieving fully competent
iPSCs at a faster rate (dotted line).earlier than nontreated controls (Huangfu et al., 2008a). There-
fore, chemical treatment can serve as a strategy to improve
both the kinetics and efficiency of reprogramming. Germline
transmission was also achieved using VPA-treated OSK iPSCs,
thus proving that VPA treatment is compatible with the induction
of pluripotency.
As reported, VPA treatment alone was insufficient to repro-
gram cells (Huangfu et al., 2008a). However, in support of
VPA’s function in promoting histone acetylation, global tran-
scriptional changeswere detected in the VPA-treated uninfected
MEFs. In particular, ESC-specific genes were upregulated while
MEF-specific genes were downregulated. Therefore, VPA may
support a predisposition toward an ESC-like state (Huangfu
et al., 2008a). In addition, the genome-wide acetylation induced
by VPA and other HDAC inhibitors could allow MEFs to adopt
a relaxed chromatin structure that facilitates the binding of
ectopically expressed transcription factors or downstream
secondary factors.
By enhancing reprogramming efficiency, VPA treatment may
facilitate a reduction in the number of reprogramming factors
required. In the presence of VPA, OSK-infected primary human
fibroblasts could be reprogrammed at a rate which is 10- to
20-fold higher than previously reported efficiencies (Huangfu
et al., 2008b). Melton and colleagues also demonstrated
that the addition of VPA enabled human fibroblasts to be
reprogrammed with two factors (OS) at an efficiency similar to
three-factor (OSK) reprogramming, thus negating the need for
exogenous KLF4 (Huangfu et al., 2008b). Notably, other combi-
nations of two factors did not yield any iPSC, even in the pres-
ence of VPA. This selective pattern suggests that OCT4 and
SOX2 are indispensable for the reprogramming of human
fibroblasts in the context of VPA treatment.
BIX, BayK, and RG108
Exogenous Sox2 is not required for the reprogramming of NSCs
andNPCs (Eminli et al., 2008; Kim et al., 2008b; Shi et al., 2008b).
However, complete reprogramming of OK-infected NPCs is an
extremely rare event, as only 0.004% of OK-infected NPCs
generate Oct4-GFP-positive colonies (Shi et al., 2008b). In
a chemical compound screen, an inhibitor of G9a histone
methyltransferase BIX-01294 (BIX) was found to improve reprog-
ramming efficiencies of OK-infected NPCs by approximately
8 fold (Shi et al., 2008b). The authors noted however that the
addition of BIX did not significantly shorten the reprogramming
process. Intriguingly, BIX treatment also bypassed the need forDNA Methyltransferase Inhibitor: AZA
The reprogramming of both mouse and human fibroblasts is an
inefficient process that occurs over an extended period of
several weeks (reviewed in Maherali and Hochedlinger, 2008).
While transcriptional effects induced by the reprogramming
factors were detected in transduced MEFs as early as day 4,
only approximately 1.2% out of 20% SSEA1-positive cells even-
tually reactivated endogenous Nanog expression after 16 days
(Mikkelsen et al., 2008). This result suggests that most infected
cells were trapped in a partially reprogrammed state due to an
inability to overcome a major reprogramming barrier. The
isolation of partially reprogrammed stable cell lines, which
morphologically resembled mouse ESCs but displayed certain
transcriptional and epigenetic differences from ESCs, supports
this notion (Meissner et al., 2007; Takahashi and Yamanaka,
2006). Despite the expression of several ESC-related genes
such as Fbx15, Fgf4, and Zic3, chimeras could not be derived
from such cell lines. Endogenous pluripotency genes such as
Oct4 and Nanog were not fully reactivated as their respective
promoters retained DNA methylation. On the other hand, viral
transgene expression remained high. By treatment with the
DNMT inhibitor 5-aza-cytidine (AZA), Meissner and colleagues
induced partially reprogrammed cells to transit the reprogram-
ming path and form iPSCs (Figure 1). The iPSCs derived with
AZA treatment reactivated endogenous Oct4, exhibited deme-
thylation at the promoters of pluripotency genes, achieved viral
silencing, and formed teratomas when injected into severe
combined immunodeficiency (SCID) mice. In addition to
promoting complete reprogramming of partially reprogrammed
cell lines, AZA also improved the number of ESC-like colonies
by 4-fold (Mikkelsen et al., 2008). This finding implies that DNA
methylation is an important epigenetic barrier that partially re-
programmed cells may encounter and fail to overcome.
Histone Deacetylase Inhibitors: VPA, TSA, and SAHA
Besides AZA, the effects of a variety of chemical inhibitors on
reprogramming have been tested. The inclusion of histone
deacetylase (HDAC) inhibitors such as valproic acid (VPA),
trichostatin A (TSA), and suberoylanilide hydroxamic acid
(SAHA) significantly enhanced reprogramming efficiencies
(Huangfu et al., 2008a). VPA treatment for a week improved
the percentage of Oct4-GFP-positive cells by more than
100-fold and 50-fold for three-factor (OSK) and four-factor
(OSKM) reprogramming, respectively. In addition, AZA and
VPA treatment induced Oct4-GFP-positive colonies 2 daysCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 305
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frequency (Shi et al., 2008b). When combined with transient
treatment of PD0325901, a MEK inhibitor that may function in
selecting or stabilizing true iPSCs, BIX treatment allowed the
derivation of OK and SKM iPSCs that were capable of germline
incorporation (Shi et al., 2008b). However, the extent of reprog-
ramming achieved with BIX alone remains unclear.
G9a is a histone methyltransferase that is known to mediate
the repression of Oct4 upon differentiation (Feldman et al.,
2006). Therefore, G9a inhibition by BIX could facilitate the reac-
tivation of Oct4 and promote reprogramming. Besides Oct4,
a recent study identified several early embryonic genes, such
as Nanog and Dnmt3l, that are inactivated by G9a (Epsztejn-
Litman et al., 2008). This capacity implicates G9a as one of the
key regulators in bringing about de novo DNA methylation and
transcriptional silencing in pluripotent cells. By inhibiting these
repressive activities of G9a, BIX could possibly derepress
pluripotency genes and also induce passive demethylation and
relaxation of chromatin in a global manner.
Recently, the positive effect of BIX on reprogramming was
extended toMEFs (Shi et al., 2008a). Unlike NPCs, BIX treatment
of OK-infected MEFs did not effectively enhance the generation
of Oct4-GFP-positive colonies. A subsequent chemical library
screen later identified DNA methyltransferase inhibitor RG108
and an L-calcium channel agonist BayK8644 (BayK) as small
molecules that can significantly enhance the reprogramming of
BIX-treated MEFs in the absence of Sox2 and c-Myc. This study
highlights how cocktails of chemicals may be concocted to
further mediate reprogramming. However, the mechanism by
which BayK acts is unclear. BayK alone or in combination with
BIX neither altered proliferation rates nor Sox2 expression
(Shi et al., 2008a). Whether BayK affects reprogramming in
a BIX-dependent or BIX-independent manner also awaits further
investigation.
MEK and GSK3 Pathway Inhibition
Signaling pathways can exert profound effects on the state of
pluripotent cells (Silva and Smith, 2008). Maintenance of the
self-renewing state of mouse ESCs has long been known to
depend on Leukemia Inhibitory Factor (LIF) and serum/Bone
Morphological Protein (BMP) (Niwa et al., 1998; Ying et al.,
2003). Besides the LIF and BMP pathways, a striking role of
both mitogen activated protein kinase/ERK kinase (MEK) and
glycogen synthase kinase-3 (GSK3) signaling pathways has
also been uncovered in mouse ESCs (Burdon et al., 1999; Ying
et al., 2008). Remarkably, concurrent inhibition of MEK and
GSK pathways can completely bypass the requirement for LIF
and serum/BMP. Stimulation of the ERK signaling pathway trig-
gers the transition of pluripotent ESCs from self-renewal to
lineage commitment (Kunath et al., 2007). Therefore, by blocking
lineage commitment induced by the ERK signaling pathway, the
ground state of ESC self-renewal could be maintained (Ying
et al., 2008). On the other hand, the inhibition of GSK3 was
proposed to enhance ESC propagation (Sato et al., 2004).
Rat is another important animal model, as this species is phys-
ically and pharmacologically more relevant to human systems
(Jacob and Kwitek, 2002). Authentic rat ESCs that are amenable
to genetic manipulation have long been desired. However, puta-
tive rat pluripotent stem cells obtained using traditional mouse306 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.ESC derivation protocols failed to generate chimera robustly
and are incompetent at achieving germline transmission. Intrigu-
ingly, the inhibition of MEK and GSK3 pathways also enables the
derivation and maintenance of genuine rat ESCs that are able to
form embryoid bodies, contribute to chimera, and are germline
competent (Buehr et al., 2008; Li et al., 2008). These findings
suggest a species conservation of fundamental mechanisms
underlying self-renewal and highlight the importance of perturb-
ing certain signaling pathways to activate the innate ability of
ESC to self-renew.
With respect to reprogramming, the dual inhibition (2i) of MEK
and GSK3 promoted the transformation of pre-iPSCs into
ground state pluripotent cells (Silva et al., 2008). Despite the
emergence of many ESC-like colonies after the OSKM transduc-
tion of NSCs, only 2% of cells were positive forOct4-driven GFP.
Cells that morphologically resembled ESCs, but were not GFP
positive, were considered as being trapped at a pre-iPSC state.
Pre-iPSCs were characterized by a downregulation of somatic
cell marker genes, incomplete reactivation of pluripotency
genes, and the maintenance of viral expression. In addition,
pre-iPSCs lacked the competency to form chimeras (Silva
et al., 2008). Treatment with the potent combination of 2i (MEK
inhibitor PD0325901 and GSK3 inhibitor CHIR99021) and LIF
modulated the transition of pre-iPSCs to fully competent iPSCs
that satisfied stringent criteria of pluripotency (Figure 1).
Reprogramming is likely to induce drastic molecular changes
that involve both the upregulation of pluripotency genes and
repression of differentiation genes. By blocking routes to differ-
entiation, one may be able to more effectively direct transduced
cells back along the desired path toward pluripotency. Evidence
suggests that differentiation may be an option for some cells as
they are being reprogrammed. It was observed that OKM-trans-
duced NSCs exhibited a higher rate of reprogramming as
compared to when Sox2 was also transduced (Eminli et al.,
2008; Silva et al., 2008). Since NSCs already express Sox2 at
sufficient levels, the introduction of more Sox2 could promote
differentiation instead of supporting the full reprogramming of
pre-iPSCs. Controlling the balance between differentiation and
pluripotency may, therefore, be fine-tuned experimentally by
the rational application of chemical inhibitors.
Treatment with 2i/LIF efficiently induced fully-competent
iPSCs from both MEF-derived and NSC-derived pre-iPSC
clones (Silva et al., 2008). However, the direct application of 2i/
LIF was ineffective on recently infected MEFs, compared to
NSCs treated at the outset of the reprogramming protocol.
Such a disparity may reflect the importance of varying reprog-
ramming kinetics among different cell types. Apparently, NSCs
require fewer days to be reprogrammed than MEFs. While reac-
tivation of Oct4-driven GFP occurred within 5 days of infection
for NSCs, the same hallmark was only observed after 3 weeks
for infected MEFs (Silva et al., 2008). Therefore, infected NSCs
may achieve certain changes associated with reprogramming
more rapidly and are thus more responsive to the 2i/LIF treat-
ment as compared to infected MEFs. Furthermore, Smith and
colleagues reported better effectiveness of 2i/LIF on NSC
reprogramming when chemical treatment was applied at day 5
rather than day 3. It is thus likely that 2i/LIF functions best within
a specified time frame of the reprogramming process. Treating
early populations of infected cells with 2i/LIF may ironically be
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and Blenis, 2004).
TGFb Pathway Inhibition
The strategic combination of transcription factor transduction
and chemical treatment can provide a powerful means to
generate new types of pluripotent cells. The differences between
mouse and human ESCs among various traits including
morphology, growth characteristics, and signaling requirements
have long been puzzling (Rossant, 2008). The derivation of
mouse epiblast stem cells (EpiSCs) from postimplantation
embryos (Brons et al., 2007; Tesar et al., 2007) has further led
to the suspicion that human ESCs are not the stage-equivalent
of mouse ESCs. While mouse ESCs are maintained by the LIF/
STAT3 and BMP signaling pathways, human ESCs and mouse
EpiSCs depend on fibroblast growth factor (FGF) and TGFb/
Activin/Nodal signaling (Yu and Thomson, 2008). Extending the
positive effects of 2i on reprogramming, Ding and colleagues
recently derived rat and human iPSCs that exhibit mouse
ESC-like traits by combining 2i with A-83-01, an inhibitor for
the TGF-b pathway. The reprogrammed cells generated from
human fibroblasts and rat liver progenitors resembled mouse
ESCs and iPSCs, in that they form domed colonies (Li et al.,
2009). Notably, the mouse-like rat iPSCs and human iPSCs
could be stably maintained in LIF and in the presence of 2i and
A-83-01, which typically induce human ESCs to differentiate.
While human ESCs require FGF2 for maintenance of an undiffer-
entiated state (Dvorak et al., 2005), themouse-like rat and human
iPSCs could be propagated long-term without any exogenous
FGF2 (Li et al., 2009). Therefore, these mouse-like iPSCs that
were derived with the treatment of 2i/A-83-01 represent cell
types that appear distinct from previously isolated murine
EpiSCs and human ESCs. In addition to in vitro differentiation
assays and teratoma formation, the rat iPSCs can also con-
tribute to chimerism (Li et al., 2009). Although the gold standard
of pluripotency, which is germline transmission, remains to be
demonstrated, the establishment of rat iPSCs provides an
example of what can be achieved through the combination of
transcription-factor-induced reprogramming and small-mole-
cule modulation of cell signaling.
Wnt Signaling Pathway Activation
The Wnt signaling pathway is implicated in promoting the self-
renewal of both mouse and human ESCs through the
aforementioned inhibition of GSK3 and the subsequent nuclear
accumulation of b-catenin (Sato et al., 2004).When the canonical
Wnt signaling pathway is stimulated, b-catenin translocates into
the nucleus where it interacts with Tcf/Lef proteins to activate
target genes (Grigoryan et al., 2008). Interestingly, Wnt3a-condi-
tioned medium promoted the reprogramming of doxycyclin
(dox)-inducible OSK-MEFs by as much as 20-fold (Marson
et al., 2008). Conditioned media from control fibroblasts also
moderately improved reprogramming, suggesting that normal
fibroblasts secrete soluble molecules beneficial to the reprog-
ramming process. In addition to the direct enhancement of
reprogramming efficiencies by Wnt3a-conditioned medium
(Marson et al., 2008), Wnt3a also enhanced somatic cell reprog-
ramming mediated by cell fusion (Lluis et al., 2008).It remains unclear how stimulation of the Wnt pathway facili-
tates reprogramming. In particular, it would be interesting to
identify important downstream effectors of Wnt that participate
in the process. For example, a prominent downstream regulator
of theWnt pathway is c-Myc (Cole et al., 2008; He et al., 1998). In
contrast to dox-inducible OSK-mediated reprogramming of
MEFs, the expression of OSKM in MEFs cultured using Wnt3a-
conditioned medium only resulted in a subtle increase in colony
formation upon dox induction. Therefore, it is possible that the
effects of Wnt3a on reprogramming were at least partially medi-
ated by c-Myc. However, the enhancement of reprogramming
efficiencies by Wnt3a-conditioned medium was not accompa-
nied by an upregulation of c-Myc in either the iPSC or cell-fusion
studies (Lluis et al., 2008; Marson et al., 2008). Given this result,
one may speculate that c-Myc and Wnt3a instead play partially
redundant roles during iPSC reprogramming.
Another candidate effector of the Wnt signaling pathway is
Tcf3. Tcf3 highly colocalizes with ESC core regulators Oct4,
Sox2, and Nanog to regulate the balance between ESC pluripo-
tency and differentiation (Cole et al., 2008; Tam et al., 2008;
Yi et al., 2008). In addition, Tcf3 also regulates itself and the
core ESC transcription factors. While Tcf3 serves as a repressor
of Oct4 and Nanog under standard ESC culture conditions,
stimulation of the Wnt pathway by treating mouse ESCs with
Wnt3a-conditioned medium led to an increased expression of
Oct4 and Nanog (Cole et al., 2008). Whether Tcf3 is connected
to reprogramming or Wnt3a acts by a Tcf3-independent
pathway awaits elucidation.
Interplay between Genetic Factors and Small Molecules
in Inducing Pluripotency
It is remarkable that the introduction of transcription factors
alone can induce pluripotency. This finding argues for a dominant
role of the core reprogramming factors over epigenetic influence
in achieving reprogramming (Niwa, 2007). Pluripotent stem cells
exhibit several unique epigenetic features (Meshorer andMisteli,
2006). For example, ESC chromatin is enriched in active marks
(methylation of H3K4 and acetylation of H3 and H4) and deficient
in silencing modifications (methylation of H3K9). Differentiation
of ESCs is accompanied by global changes in histone modifica-
tions and a transition to a transcriptionally less permissive chro-
matin state characterized by a decrease in H3K4Me3 and an
elevation of H3K9methylation (Meshorer et al., 2006). Compared
to NPCs, ESCs express elevated levels of chromatin-remodeling
factors such as Smarca4, Smarcd2, and Chd1l (Efroni et al.,
2008). How do the reprogramming factors reboot the epigenetic
state of somatic cells? In ESCs, the core transcription factors
were found to coregulate the expression of epigenetic factors
that participate in the maintenance of self-renewal and pluripo-
tency. Oct4 and Sox2 cobind to a group of genes that encode
epigenetic factors such as Smarcad1, Myst3, Jmjd1a, and
Jmjd2c (Loh et al., 2006, 2007). It is noteworthy that overexpres-
sion of Jmjd1a, a histone H3 lysine 9 demethylase, can enhance
reprogramming of NSC after cell fusion with ESCs (Ma et al.,
2008). Therefore, Oct4 and other reprogramming factors may
actively regulate the expression of epigenetic factors that further
participate in the reprogramming process.
Recent reprogramming studies have shown that small mole-
cules such as AZA, VPA, and BIX can improve reprogrammingCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 307
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Species Cells Conditions*
Pluripotency Assays
Performed and Passed References
Mouse ESC LIF T, C, G, TE (reviewed by Rossant, 2008)
ESC 2i+ or 3i+ T, C, G (Ying et al., 2008)
iPSC LIF T, C, G (reviewed by Maherali and Hochedlinger, 2008)
Rat ESC 3i+ C, G (Li et al., 2008)
ESC LIF, 2i+ or 3i+ T, C (Buehr et al., 2008)
iPSC LIF T, C (Liao et al., 2009)
iPSC LIF, 2i, A-83-01 T, C (Li et al., 2009)
Human ESC FGF2 T (reviewed by Yu and Thomson, 2008)
iPSC FGF2 T (reviewed by Maherali and Hochedlinger, 2008)
iPSC LIF, 2i, A-83-01 T (Li et al., 2009)
T, teratoma; C, chimera; G, germline transmission; TE, tetraploid complementation.
* Human iPSCs are cultured in knockout serum replacement medium (KSR) while mouse and rat ESCs/iPSCs are cultured in serum or KSR except for
those grown in 2i or 3i conditions which are in N2B27 media (+).308 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.pluripotent cells that are able to colonize embryos and be trans-
mitted through the germline. In another study, Blau and
colleagues reported that sodium butyrate, a histone deacetylase
inhibitor, induces both mouse ESCs and human ESCs to enter
a distinct self-renewal state that may represent an intermediate
between ESCs and EpiSCs (Ware et al., 2009). While supporting
ESC self-renewal across species, butyrate elicited differential
gene expression patterns and reduced the transcriptional differ-
ences between mouse ESCs and human ESCs. Therefore,
ectopic expression of genetic factor(s) or small-molecule treat-
ment is sufficient to alter states of pluripotency.
As current mouse and human iPSCs (Maherali et al., 2007;
Okita et al., 2007; Takahashi et al., 2007; Takahashi and Yama-
naka, 2006; Wernig et al., 2007) are similar to mouse and human
ESCs, respectively (Table 3), one may argue that human iPSCs
are more akin to EpiSCs rather than mouse ESCs in terms of
growth-factor requirement and attained pluripotency levels.
Differences in the pluripotency states may be attributed to vari-
ation in culture conditions that have preferentially selected for
particular cells during reprogramming. In other words, culture
supplements and niche environments can potentially provide
restriction on the framework of pluripotency. It is likely that the
presence of LIF and serum enables indirect selection for mouse
iPSCs in contrast to fibroblast growth factor 2 (FGF2), which
selects for epiblast-like human iPSCs. By varying culture condi-
tions during the course of reprogramming, it is also possible to
select for or induce human iPSCs that can be maintained under
the inhibition of FGF and TGFb/Activin/Nodal signaling (Li et al.,
2009). As yet, it has also not been examined whether mouse
somatic cells can be reprogrammed to EpiSC-like iPSCs in the
presence of FGF2.
The application of growth factors and signaling molecules
can be used to modulate the state of pluripotency. Geijsen
and colleagues have derived stem cells from E3.5 mouse blas-
tocysts in the presence of FGF, Activin, and BIO (a GSK-3
inhibitor) (Chou et al., 2008). Although these stem cells (also
known as FAB-SCs) exhibit certain features shared with mouse
ESCs and EpiSCs, they demonstrate limited potency in differ-
entiation. Interestingly, a transient stimulation with growthwhen combined with conventional reprogramming factors
(Huangfu et al., 2008a; Mikkelsen et al., 2008; Shi et al.,
2008b). As discussed above, these small molecules participate
in epigenetic processes, thus hinting at the importance of over-
coming epigenetic barriers during reprogramming. The relief of
repression on key pluripotency genes such as Oct4 and Nanog
may allow an earlier induction of self-renewal and pluripotency.
In addition, these chemical inhibitors could potentially induce
a global permissive epigenetic landscape similar to ESCs (Silva
and Smith, 2008) by inducing epigenetic changes that promote
an active transcriptional state and facilitating the erasure of
repressive epigenetic features. This combination of events may
provide exogenous reprogramming factors and secondarily
induced transcription factors greater access to downstream
target genes. As such, genetic factors and small molecules
may synergistically modify epigenetic features and activate an
ESC-like transcriptional program to enhance reprogramming.
Attaining Different Pluripotent States through
Reprogramming
As previously mentioned, human ESCs are intrinsically different
from mouse ESCs in both transcriptional and signaling networks
(Rossant, 2008; Yu and Thomson, 2008) and may represent
a stage-equivalent of mouse epiblast stem cells (EpiSCs) that
were established from postimplantation embryos (Brons et al.,
2007; Tesar et al., 2007). Despite an ability to differentiate into
cells of all three germ layers in embryoid body formation and
teratoma assays, EpiSCs are incapable of contribution to
chimeras (Tesar et al., 2007). Hence, EpiSCs may have acquired
restrictions with regard to their developmental potency. The
successful demonstration of interconversion between mouse
ESCs and EpiSCs further supports that the two cell types repre-
sent two distinct pluripotent states (Guo et al., 2009). When
exposed to EpiSC culture condition, mouse ESCs continue to
proliferate and gradually adopt an EpiSC-like phenotype. In
contrast, EpiSCs do not naturally revert to ESC-like status
when cultured in 2i/LIF media, which promotes the ground state
of mouse ESCs. However, by forced expression of Klf4 in the
presence of 2i/LIF, EpiSCs were reprogrammed into genuinely
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these cells. In another example, blockade of the MEK pathway
improved the derivation of authentic ESC lines from both
refractory mouse and rat (Buehr et al., 2008; Li et al., 2009;
Ying et al., 2008).
B
A
Figure 2. Chemical Screening Strategies for Reprogramming
Molecules
(A) The transcriptional activation of genes encoding for reprogramming factors
such as Oct4, Sox2, Sox1, Sox5, Klf4, Klf2, Klf5, Esrrb, and Esrrg enables the
reprogramming of somatic cells to iPSCs (Feng et al., 2009; Nakagawa et al.,
2008). High-throughput screening provides a powerful tool for the search of
chemicals that could activate each of these genes. In a context-dependent
manner, these chemicals may by-pass the requirement for certain reprogram-
ming factors. For example, it is known that BIX enabled the bypass for the need
of exogenous Oct4 in SKM-infected NPCs (Shi et al., 2008b). Chemical
screening may also reveal small molecules that activate other genes
(gene X) to enable or enhance reprogramming. Candidates for gene X are
Nanog, Lin28, and Utf1 (Yu et al., 2007b; Zhao et al., 2008). The activation of
endogenous reprogramming genes will, in turn, jump-start the ESC-specific
gene expression program. The chemicals are represented by hexagons.
(B) To avoid safety issues related to viral transduction and genomic integration,
it would be ideal to reprogram somatic cells purely by treatment with mole-
cules. Molecules such as self-renewal modulators (e.g., LIF, MEK inhibitor,
and GSK3 inhibitor), pluripotency gene activators (identified using strategy
shown in [A]), and reprogramming boosters may be combinatorially used to
induce efficient reprogramming. Reprogramming boosters could be epige-
netic modulators such as VPA or AZA that exert global activation or remove
repressive chromatin mark, respectively. Nongenetic reprogramming mole-
cules are represented by circles, hexagons, or a star.The recent derivation of rat iPSCs and human iPSCs that
resemble mouse iPSCs proposes an interesting paradigm of
how reprogramming, chemical inhibitors, and culture conditions
can together generate a variety of pluripotent iPSCs (Li et al.,
2009). The emergence of new ESCs and iPSCs will allow one
to study the intriguing differences between different pluripotent
cells. Furthermore, would it be possible to completely bypass
pluripotency and transit directly from one somatic cell type to
another desired lineage or cell type (Zhou and Melton, 2008)?
Graf and colleagues have shown that lineage switching is
possible in the hematopoietic system whereby the overexpres-
sion of C/EBPa and b is sufficient to reprogram B lymphocytes
into macrophages (Xie et al., 2004). Melton and colleagues
have also shown that a specific combination of transcription
factors can be used to reprogram adult pancreatic exocrine cells
to b-cells in vivo (Zhou et al., 2008), thus demonstrating that
ectopic expression of transcription factor(s) can drive the
conversion between adult cell types.
Future Directions
With the continued use of high-throughput screening to identify
more chemicals that could assist in reprogramming, we may
be closer to the goal of using a chemical-only cocktail to
reprogram somatic cells to iPSCs. It is conceivable that
small molecules that are able to activate each of the reprogram-
ming factors will be identified in the future (Figure 2A). These
pluripotency gene activators may be used in combination with
self-renewal modulators and/or reprogramming boosters to
drive complete reprogramming more efficiently (Figure 2B).
Previous studies that revealed chemicals that improve ESC
survival and growth may also yield candidate molecules that
can be tested for their capacity to enhance reprogramming.
For example, Rho-associated kinase (ROCK) inhibitor Y-27632
improves cloning efficiencies of human ESCs (Watanabe et al.,
2007) and also participated to increase reprogramming effi-
ciency in at least one study (Park et al., 2008). Furthermore,
epigenetic modulators such as VPA may boost the efficiency
of reprogramming. As not all cell types can be reprogrammed
with similar efficiencies, it will be useful to identify cell types
with either high levels of endogenous reprogramming factors
or that are highly permissive toward reprogramming. Under-
standing how chemicals assist in reprogramming will also allow
us to use them in a more effective way.
Beyond their capacity to promote efficient reprogramming,
several pertinent issues relating to the safety of small molecules
need to be carefully addressed before chemical-treated iPSCs
can be considered for therapeutic applications. Besides exerting
known localized changes, chemicals used for reprogramming
may promote global modifications. Most of these changes
remain unidentified and may result in genetic aberrations and/
or dysregulation of genes. For example, AZA is known to induce
DNA damage (Palii et al., 2008). Rigorous tests should therefore
be performed to ensure that transient chemical treatments do
not result in permanent genomic or epigenomic alterations. In
addition, an optimization of the dosage and duration of chemical
treatment would be necessary to maximize efficacy while
reducing toxicity. Chemical modifications can also be done to
further enhance the efficiency of these drugs with respect to
reprogramming.Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 309
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strategies that avoid the issue of viral transduction and genomic
integration are under active development. Adenoviral transduc-
tion (Stadtfeld et al., 2008) and transient transfection (Okita
et al., 2008) have been undertaken to circumvent the issue of
oncogenic transgene integration into the genome. However,
such methods have only been demonstrated in reprogramming
of mouse cells and the achieved reprogramming efficiencies
were extremely low. More recently, the piggyBac (PB) trans-
poson gene-delivery system has been introduced to achieve
reprogramming without permanent viral integration (Kaji et al.,
2009; Woltjen et al., 2009). This system requires only the inverted
terminal repeats flanking transgene and transient expression of
the tranposase to catalyze insertion. After the iPSC clones
were established, the integrated transgene can be eliminated
from the genome by Cre (Kaji et al., 2009) or PB transposase-
mediated excision (Woltjen et al., 2009). Other features of the
PB system, such as high transposition activity, precise excision,
and good genomic coverage (Wang et al., 2009; Wang et al.,
2008), are extremely useful for genome-wide screens for novel
reprogramming factors.
Currently, it may be difficult to compare reprogramming
frequencies between different studies due to variation in
transduction efficiencies and clone isolation methods (reviewed
in Maherali and Hochedlinger, 2008). Furthermore, reported
reprogramming frequencies are often based on different criteria
such as alkaline phosphatase activity and activation of reporter
genes. Although chimera contribution and germline transmission
serve as more rigorous demonstrations of reprogramming,
quantification of such qualities is technically tedious and may
not serve as a relevant criterion for future clinical applications
of human iPSCs. Nevertheless, robust criteria that allow full
quantitative assessment of pluripotency remain to be investi-
gated.
Concluding Remarks
Recent studies have provided new strategies to improve the
reprogramming process. The minimal set of transcription factors
required to induce reprogramming is constantly being refined,
while the application of molecules such as chemical inhibitors
and signaling molecules rapidly gain in importance. Chemical
inhibitors involved in DNA methylation, histone methylation,
and acetylation not only improve reprogramming efficiencies
and kinetics, but also bypass the addition of certain reprogram-
ming factors. Other molecules, such as Wnt3a, 2i, and A-83-01,
may alter the signaling states of cells undergoing reprogramming
and drive the complete transition into full-term iPSCs. Combina-
torially, genetic factors and small molecules represent a powerful
strategy for one to derive a variety of pluripotent cell types.
However, it still remains a challenge to reprogram somatic cells
purely by chemical treatment. Screening for molecular
compounds that can facilitate transcriptional bypass or induce
transitions between specific differentiated cell types will also
provide invaluablemechanistic insights and possible therapeutic
applications. The field has, indeed, entered an exciting era in
which we have witnessed the reversibility of committed cell
fate through the use of transcription factors and other molecules
to instruct the genomic template to jump-start the pluripotency
engine.310 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.ACKNOWLEDGMENTS
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